BCRX
HEALTHCAREBiocryst Pharmaceuticals Inc
$8.83-0.20 (-2.21%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving BCRX Today?
No stock-specific AI insight has been generated for BCRX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$6.00$11.31
$8.83
Fundamentals
Market Cap$2.2B
P/E Ratio—
EPS$-1.77
Dividend Yield—
Dividend / Share—
ROE-19.3%
Profit Margin-0.5%
Debt / Equity—
Trading
Volume9.0M
Avg Volume (10D)—
Shares Outstanding254.1M
BCRX News
20 articles- BioCryst (BCRX) Q1 2026 Earnings TranscriptMotley Fool·May 6, 2026
- BioCryst Pharmaceuticals, Inc. Q1 2026 Earnings Call SummaryMoby·May 6, 2026
- BioCryst Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·May 6, 2026
- BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 6, 2026
- BioCryst Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 6, 2026
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 5, 2026
- BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary AngioedemaYahoo Finance·May 4, 2026
- Is It Time To Reassess BioCryst Pharmaceuticals (BCRX) After Its Recent Share Price GainsYahoo Finance·May 3, 2026
- RBC Capital Lifts PT BioCryst Pharmaceuticals (BCRX) as Part of Q1 2026 Results Preview in BiotechYahoo Finance·May 1, 2026
- KalVista Scores $1.9 Billion Takeover Deal; Why A Key Rival Jumped TooYahoo Finance·Apr 29, 2026
- BioCryst to Present at Upcoming Investor ConferencesYahoo Finance·Apr 28, 2026
- BioCryst to Report First Quarter 2026 Financial Results on May 6Yahoo Finance·Apr 15, 2026
- BioCryst Appoints Sandeep M. Menon Chief Research and Development OfficerGlobeNewswire Inc.·Apr 6, 2026
- How The BioCryst Pharmaceuticals (BCRX) Narrative Is Shifting With Astria Deal And FY26 TargetsYahoo Finance·Apr 5, 2026
- BioCryst Shares Remain Undervalued, RBC SaysYahoo Finance·Mar 25, 2026
- BioCryst (BCRX) Rallies 7.10% on Acquisition BuzzYahoo Finance·Mar 20, 2026
- BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy Now?Yahoo Finance·Mar 19, 2026
- BioCryst Takeover Rumors Test Investor Focus On Fundamentals And OptionalityYahoo Finance·Mar 19, 2026
- BioCryst (BCRX) Soars 13% on Acquisition BuzzYahoo Finance·Mar 17, 2026
- BioCryst Pharma (BCRX) Subject to Prise Target Raise by WedbushYahoo Finance·Mar 10, 2026
All 20 articles loaded
Price Data
Open$9.22
Previous Close$9.03
Day High$9.31
Day Low$8.94
52 Week High$11.31
52 Week Low$6.00
52-Week Range
$6.00$11.31
$8.83
Fundamentals
Market Cap$2.2B
P/E Ratio—
EPS$-1.77
Dividend Yield—
Dividend / Share—
ROE-19.3%
Profit Margin-0.5%
Debt / Equity—
Trading
Volume9.0M
Avg Volume (10D)—
Shares Outstanding254.1M
About Biocryst Pharmaceuticals Inc
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small molecule drugs. The company is headquartered in Durham, North Carolina.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—